Liposomes Modified by Carbohydrate Ligands Can Target B Cells for the Treatment of B-cell Lymphomas

Overview

Journal Expert Rev Vaccines

Date 2010 Nov 20

PMID 21087105

Citations 4

Authors

Geert-Jan Boons

Affiliations

Soon will be listed here.

Abstract

Evaluation of: Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 115(23), 4778-4786 (2010). A strategy has been developed to deliver selectively chemotherapeutic drugs to B cells by employing doxorubicin-loaded liposomes modified by a ligand for the B-cell-specific cell-surface protein CD22, also known as Siglec-2. The liposomes bound in a rapid and saturable manner to the human Burkitt lymphoma Daudi B-cell line and exhibited significantly higher cytotoxicity in vitro and in vivo compared with similar untargeted liposomes. The CD22-targeted liposome bound to B cells isolated from lymphoma patients and although binding was proportional to CD22 expression on the cell surface, low levels of expression on chronic lymphocytic leukemia cells were sufficient to effect cell neutralization. The glycan-based strategy for delivery of chemotherapeutic agents may provide a new strategy for the treatment of B-cell lymphomas.

Citing Articles

Enzymatic elaboration of oxime-linked glycoconjugates in solution and on liposomes.

Silva J, Spiess R, Marchesi A, Flitsch S, Gough J, Webb S J Mater Chem B. 2022; 10(26):5016-5027.

PMID: 35723603 PMC: 9258907. DOI: 10.1039/d2tb00714b.

Effects of linker and liposome anchoring on lactose-functionalized glycomacromolecules as multivalent ligands for binding galectin-3.

Freichel T, Laaf D, Hoffmann M, Konietzny P, Heine V, Wawrzinek R RSC Adv. 2022; 9(41):23484-23497.

PMID: 35530592 PMC: 9069326. DOI: 10.1039/c9ra05497a.

Methods of Liposomes Preparation: Formation and Control Factors of Versatile Nanocarriers for Biomedical and Nanomedicine Application.

Lombardo D, Kiselev M Pharmaceutics. 2022; 14(3).

PMID: 35335920 PMC: 8955843. DOI: 10.3390/pharmaceutics14030543.

Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery.

McCallion C, Peters A, Booth A, Rees-Unwin K, Adams J, Rahi R Blood Adv. 2019; 3(14):2069-2081.

PMID: 31292126 PMC: 6650733. DOI: 10.1182/bloodadvances.2019000098.

References

Chen W, Completo G, Sigal D, Crocker P, Saven A, Paulson J . In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood. 2010; 115(23):4778-86. PMC: 2890185. DOI: 10.1182/blood-2009-12-257386. View

Bruehl R, Dasgupta F, Katsumoto T, Tan J, Bertozzi C, Spevak W . Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. Biochemistry. 2001; 40(20):5964-74. DOI: 10.1021/bi002921s. View

Hashida N, Ohguro N, Yamazaki N, Arakawa Y, Oiki E, Mashimo H . High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp Eye Res. 2007; 86(1):138-49. DOI: 10.1016/j.exer.2007.10.004. View

Kreitman R, Wilson W, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald D . Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001; 345(4):241-7. DOI: 10.1056/NEJM200107263450402. View

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3):754-8. DOI: 10.1182/blood.v99.3.754. View

Ikehara Y, Niwa T, Biao L, Ikehara S, Ohashi N, Kobayashi T . A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res. 2006; 66(17):8740-8. DOI: 10.1158/0008-5472.CAN-06-0470. View

Molina A . A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008; 59:237-50. DOI: 10.1146/annurev.med.59.060906.220345. View

Levine A, Tulpule A, Espina B, Sherrod A, Boswell W, Lieberman R . Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004; 22(13):2662-70. DOI: 10.1200/JCO.2004.10.093. View

Collins B, Blixt O, DeSieno A, Bovin N, Marth J, Paulson J . Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci U S A. 2004; 101(16):6104-9. PMC: 395930. DOI: 10.1073/pnas.0400851101. View

10.

Alas S, Emmanouilides C, Bonavida B . Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001; 7(3):709-23. View

11.

Imai K, Takaoka A . Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6(9):714-27. DOI: 10.1038/nrc1913. View

12.

Zaccai N, Maenaka K, Maenaka T, Crocker P, Brossmer R, Kelm S . Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure. 2003; 11(5):557-67. DOI: 10.1016/s0969-2126(03)00073-x. View

13.

Bowles J, Wang S, Link B, Allan B, Beuerlein G, Campbell M . Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006; 108(8):2648-54. PMC: 1895597. DOI: 10.1182/blood-2006-04-020057. View

14.

Morphy R, Kay C, Rankovic Z . From magic bullets to designed multiple ligands. Drug Discov Today. 2004; 9(15):641-51. DOI: 10.1016/S1359-6446(04)03163-0. View

15.

Crocker P, Paulson J, Varki A . Siglecs and their roles in the immune system. Nat Rev Immunol. 2007; 7(4):255-66. DOI: 10.1038/nri2056. View

16.

Castillo J, Winer E, Quesenberry P . Newer monoclonal antibodies for hematological malignancies. Exp Hematol. 2008; 36(7):755-68. DOI: 10.1016/j.exphem.2008.04.018. View

17.

Selenko N, Maidic O, Draxier S, Berer A, Jager U, Knapp W . CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia. 2001; 15(10):1619-26. DOI: 10.1038/sj.leu.2402226. View

18.

Cheng W, Allen T . Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release. 2007; 126(1):50-8. DOI: 10.1016/j.jconrel.2007.11.005. View

19.

Kreitman R, Margulies I, Stetler-Stevenson M, Wang Q, Fitzgerald D, Pastan I . Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res. 2000; 6(4):1476-87. View

20.

OReilly M, Paulson J . Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci. 2009; 30(5):240-8. PMC: 2830709. DOI: 10.1016/j.tips.2009.02.005. View